top of page
Group Photo 2022_IMG_4744.JPEG

CEBINA is led by a team of highly experienced academic and medical research scientists and entrepreneurs with decades-long experience in product development and biotech innovation

Management Team

Eszter Nagy, MD, PhD

CEO, CSO Founder

Over 20 years of biotech experience and serial entrepreneurship, successfully raising >€40M VC financing and €16M non-dilutive funding

Co-founder, CEO Calyxha Biotechnologies GmbH; Co-founder, president Eveliqure Biotechnologies GmbH; CEO, CSO Algonist Biotechnologies GmbH

Previously:  Co-founder & CSO Arsanis, Inc (IPO, NASDAQ 2017, now X4 Pharma); SVP Research, Intercell AG (now Valneva SAS)

Mag. Wolfgang Friedl

Chief Operating Officer

CEBINA operations, facility, investor relations and legal

Attorney at Law, founder and senior partner of Vienna Legal Group; CEO MAG-LAB

Over 25 years experience in corporate law, national / international M&A, and financing with a strong focus on biotech

Sophie Zettl, PhD

Chief Business Officer

Business development, intellectual property, PR and communications

Over 15 years licensing / BD / IP experience in biotech, Pharma and University Technology Transfer Offices​; CBO, COO Algonist Biotechnologies GmbH


Previously: Arsanis Inc, MedImmune / AstraZeneca, University College London, King’s College London

Gábor Nagy MD, PhD

VP Research & Technology Evaluation

14 years biotech R&D experience


Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH (co-founder), Intercell AG (now Valneva SAS)

Valéria Szijártó, MD, PhD, MBA

VP Preclinical & Translational Research

10 years biotech R&D experience

Professional MBA in Entrepreneurship and Innovation at WU Executive Academy, Vienna


Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH 

Vanja Nagy, PhD

DanubeNeuro Program Director

Previously: Group leader and co-founder at the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Austria; Adjunct Principal Investigator at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, and  Lecturer at the Medical University of Vienna.

Martina Bellasio, PhD

Senior Business Development Manager

7 years industrial biotech and product management experience

Project scouting and evaluation for Danube Labs and DanubeNeuro

Advisors and Investments

Patrick Aisher

Strategic investor / Investment advisor

Chairman of Kinled Holding, serial entrepreneur who has invested in the life science industry since 1997. Focus on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services, with direct investments in over 50 businesses, 24 exiting via IPO, trade sale or licensing.


Director of Aleva Neurotherapeutics SA, PreComb Therapeutics AG, has identified and invested in early-stage spin-off opportunities from Universities in Barcelona, Zurich, Oxford, Boston, Stanford, NorthEastern, Texas, NYU, Lausanne and Geneva.

January 27, 2020310.jpg
Fabio Blom

Investment Committee Member​

bottom of page